Oncolytics Biotech (TSX:ONC) Interest Income : C$1.20 Mil (TTM As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Oncolytics Biotech's interest income for the three months ended in Dec. 2024 was C$0.15 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2024 was C$1.20 Mil.

Oncolytics Biotech Interest Income Historical Data

The historical data trend for Oncolytics Biotech's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Interest Income Chart

Oncolytics Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Income

Get a 7-Day Free Trial

0.12

0.10

0.53

1.33

1.20

Oncolytics Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Income	Get a 7-Day Free Trial															0.49	0.45	0.34	0.26	0.15

Oncolytics Biotech Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.20 Mil.

Oncolytics Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

ONCY:USA

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Executives